ABSTRACT
Portador de carcinoma espinocelular da conjuntiva teve a lesão removida, com recorrência em outra localização. O paciente recebeu ciclos de 5-Fluoruracila como tratamento adjuvante à remoção cirúrgica, apresentando evolução desfavorável que chegou à exenteração orbitária. São feitos comentários quanto ao uso de antimitóticos no tratamento destas lesões.
A case of a squamous cell carcinoma of the conjunctiva is presented. The lesion was removed with recurrence in another conjunctival site. The patient received cycles of 5-Fluorouracil as adjuvant treatment to the surgical removal and presented unfavorable evolution, requiring orbital exenteration. Comments are made on the use of antimitotic drugs in the management of these lesions.
Subject(s)
Aged , Humans , Male , Carcinoma, Squamous Cell/therapy , Conjunctival Neoplasms/therapy , Orbit Evisceration , Orbital Neoplasms/therapy , Antimetabolites, Antineoplastic/therapeutic use , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy/methods , Conjunctival Neoplasms/pathology , Fluorouracil/therapeutic use , Neoplasm Recurrence, Local , Orbital Neoplasms/pathologyABSTRACT
Objective To observe the effects of modified Yigong Powder (MYP) combined with chemotherapy on transplanted hepatocarcinoma of mice and to study its mechanisms. Methods Hepatocarcinoma 22 mouse model was established and then was used to observe the attenuating and synergic effects of MYP when applied together with 5-fluorouracil (5-FU). After 8 days of treatment,the tumor-inhibiting rate,activity of natural killer (NK)cells and interleukin-2 (IL-2) and small intestinal malondialdehyde (MDA) content were examined. Results MYP combined with 5-FU could increased the tumor-inhibiting rate to some extent and improve the immune function by increasing immune organ weight and increasing the activity of NK cells and IL-2. MYP combined with 5-FU could also reduce the 5-FU-induced intestinal injuries by relieving the damage of free radicals and inhibiting the lipid peroxidation and a good prognosis was expected in tumor-bearing animals treated with chemotherapy. Conclusion MYP exerts an attenuating and synergic effect when used together with 5-FU in treating tumor-bearing mice and its mechamism may be related to the improvement of immune function and reduction of intestinal injuries.